August 11, 2021
Video
Experts share final thoughts and advice for clinicians in the community to help optimize treatment success in CLL.
August 09, 2021
Emerging combination therapies and novel agents being studied as initial therapy for CLL are discussed.
August 04, 2021
Experts discuss factors and approaches to consider if choosing between a BTKi-based and BCL2i-based regimen for frontline therapy in CLL.
August 02, 2021
Kirollos S. Hanna, PharmD, BCPS, BCOP, discusses data on a BCL2 inhibitor in combination with anti-CD20 monoclonal antibodies in the treatment of CLL.
July 26, 2021
Taylor M. Weis, PharmD, BCOP, discusses data on a BTK inhibitor in combination with anti-CD20 monoclonal antibodies in the treatment of CLL.
Experts discuss the results of a head-to-head trial of ibrutinib versus acalabrutinib in CLL and the cardiovascular toxicity associated with BTK inhibitors.